Grace Overview
This company is a known business entity but lacks sufficient data to support a standard Finder profile.
Latest News
growth-positive
Former Verbit CEO Tom Livne launches new startup, leveraging AI to tackle drug development challenges
Grace, co-founded by Tom Livne, aims to repurpose abandoned drugs using AI technology. The company is preparing to raise its first funding round, targeting $10–20 million from local and international investors. Livne, known for founding Verbit, has invested hundreds of thousands of dollars of his own money into Grace. His partners in the venture are Shay Liraz and David Futorian, both graduates of the elite Talpiot program. Graces AI-powered software will analyze data from discontinued drugs to identify new development possibilities. The company is in the clinical trial stage and is expected to leverage AI technology for drug discovery.
InvestmentPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Pre-Funding |
| Rounds | 0 |
| Investors | 0 |
Team Members
3
Employees: 1-10
Web & Social Links
Locations
Israel
Photos & Videos
No files yet
Grace Business
Business models
—
Product stage
R&D
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDigital HealthcareTarget Customer
—Core Technology
Artificial IntelligenceTags (1)
stealthmodeGrace Financials
Undisclosed
Total funding
—
Capital raised
Undisclosed
Last funding
Pre-Funding
Funding stage
0
Total rounds
0
Investors
Grace Lifecycle
Grace News
1 article
growth-positive
Former Verbit CEO Tom Livne launches new startup, leveraging AI to tackle drug development challenges
Grace, co-founded by Tom Livne, aims to repurpose abandoned drugs using AI technology. The company is preparing to raise its first funding round, targeting $10–20 million from local and international investors. Livne, known for founding Verbit, has invested hundreds of thousands of dollars of his own money into Grace. His partners in the venture are Shay Liraz and David Futorian, both graduates of the elite Talpiot program. Graces AI-powered software will analyze data from discontinued drugs to identify new development possibilities. The company is in the clinical trial stage and is expected to leverage AI technology for drug discovery.
InvestmentPartners
Grace Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 3 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 4 classification IDs that could be used for matching.
Grace Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 50/100 |
| Missing | sector, tags, business model, logo, description, homepage, video or image, funding rounds, markets, external profiles, not claimed |
| BI Verification | Matan Eblagon |
| Creator | Matan Eblagon |
| Creator email | matane@sncentral.org |
| Last update | 2025-01-08T00:00:00.000Z |
| Created | 2025-01-08T00:00:00.000Z |